MMWR recomm. rep; 72 (2), 2023

Most of the influenza vaccines currently approved and available in the United States are produced by the propagation of influenza viruses in eggs (1-7). These vaccines therefore can contain small quantities of egg proteins. As of the 2022-23 influenza season, ACIP has recommended annual influenza vacci...

Fulltext

MMWR recomm. rep; 79 (29), 2023

A Grading of Recommendations, Assessment, Development and Evaluation (GRADE) review of the evidence for benefits and harms for GSK Respiratory Syncytial Virus (RSV) PreF3 vaccine was presented to the Advisory Committee on Immunization Practices (ACIP) on June 21, 2023. GRADE evidence type indicates the c...

Fulltext

MMWR recomm. rep; 79 (29), 2023

A Grading of Recommendations, Assessment, Development, and Evaluation (GRADE) review of the evidence for benefits and harms for Pfizer Respiratory Syncytial Virus (RSV) preF vaccine was presented to the Advisory Committee on Immunization Practices (ACIP) on June 21, 2023. GRADE evidence type indicates th...

Fulltext

MMWR recomm. rep; 71 (1), 2022

Estimated rates of influenza-associated hospitalization and death are generally highest among individuals 65 years of age and older (1-4), an age group for whom influenza vaccine effectiveness is often lower relative to younger populations (5, 6). Two inactivated influenza vaccines approved in the U.S. f...

Fulltext